Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report)'s stock price hit a new 52-week low during trading on Monday . The company traded as low as $15.67 and last traded at $15.98, with a volume of 228784 shares traded. The stock had previously closed at $16.42.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on KROS shares. Guggenheim lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a research note on Monday, December 16th. Truist Financial cut their price target on Keros Therapeutics from $100.00 to $43.00 and set a "buy" rating on the stock in a report on Monday, December 23rd. HC Wainwright decreased their price objective on Keros Therapeutics from $100.00 to $47.00 and set a "buy" rating for the company in a report on Friday, December 13th. Oppenheimer dropped their target price on Keros Therapeutics from $102.00 to $63.00 and set an "outperform" rating on the stock in a research report on Monday, December 16th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $75.00.
View Our Latest Report on KROS
Keros Therapeutics Trading Down 4.8 %
The company has a market cap of $633.53 million, a P/E ratio of -3.00 and a beta of 1.20. The business has a 50 day moving average price of $50.54 and a 200-day moving average price of $50.50.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company's revenue was up 4750.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.33) EPS. On average, sell-side analysts expect that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current year.
Institutional Investors Weigh In On Keros Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. increased its position in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after buying an additional 280 shares during the last quarter. KBC Group NV boosted its stake in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company's stock worth $73,000 after acquiring an additional 432 shares during the period. Point72 Asia Singapore Pte. Ltd. increased its holdings in shares of Keros Therapeutics by 36.7% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company's stock worth $223,000 after acquiring an additional 1,033 shares during the last quarter. Arizona State Retirement System raised its stake in Keros Therapeutics by 16.3% in the 2nd quarter. Arizona State Retirement System now owns 8,077 shares of the company's stock valued at $369,000 after acquiring an additional 1,130 shares during the period. Finally, Algert Global LLC lifted its holdings in Keros Therapeutics by 10.6% during the 2nd quarter. Algert Global LLC now owns 15,700 shares of the company's stock valued at $717,000 after purchasing an additional 1,505 shares during the last quarter. 71.56% of the stock is owned by institutional investors.
Keros Therapeutics Company Profile
(
Get Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Further Reading
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
